The recent surge in psychedelic therapeutics’ acceptance has seemingly caught the eye of the U.S. Congress. On September 21, 2023, Congressmen Robert Garcia (CA-42) and Earl Blumenauer (D-OR) introduced what is known as the “Validating Independence for State Initiatives on Organic Natural Substances Act of 2023,” a title shortened to the aptly named VISIONS Act.
If enacted, this legislation would offer protection for legal psilocybin use from any federal law enforcement intervention in states or localities where psilocybin is legally permitted. As a result, it echoes a trend of increasing accommodation for psychedelics at the state level, potentially reducing the discrepancy between state and federal legislation that has dogged other substances, such as marijuana, for many years.
In the context of federal law, this move is significant. Psilocybin – the hallucinogenic compound found in many species of mushrooms – currently resides in the same category as substances like heroin and LSD. That classification, as defined by the United States Controlled Substances Act, indicated that these substances have no currently accepted medical use and a high potential for abuse.
Yet, the VISIONS Act could mark a turning point. The bill, as outlined by JD Supra, could give states the room to independently legislate on the legality of substances like psilocybin and possibly widely enlarge the scope for further research into and therapeutic use of these substances.
There appears to be a shift in attitudes towards psychedelics, with mounting evidence indicating potential therapeutic benefits for mental health conditions where traditional treatments may have been insufficient. However, the interdisciplinary world of law, policy, science, and medicine must navigate carefully in order to reap these potential benefits while minimizing the risks. This proposed legislation, if successful, may well provide a structured, legally sound environment in which to do so.